SCHEMBL21990688

SCHEMBL21990688

NCc1nc(Cl)cc2c1CNC2=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.40
PIM1 P11309 3/20 0.33
FLT3 P36888 3/20 0.33
CDK5 Q00535 3/20 0.33
ROCK1 Q13464 3/20 0.33
CLK4 Q9HAZ1 3/20 0.33
NTRK1 P04629 2/20 0.33
PRKACA P17612 2/20 0.33
PLK4 O00444 2/20 0.33
CHEK1 O14757 2/20 0.33
ROCK2 O75116 2/20 0.33
PRKD3 O94806 2/20 0.33
MAP4K4 O95819 2/20 0.33
PRKCG P05129 2/20 0.33
LCK P06239 2/20 0.33
RET P07949 2/20 0.33
RPS6KB1 P23443 2/20 0.33
PRKCI P41743 2/20 0.33
CSNK1D P48730 2/20 0.33
RPS6KA3 P51812 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21990566 0.84 GRM2 (0.35) DPP4PIM1FLT3CDK5ROCK1
SCHEMBL30543379 0.78 CLK4 (0.37) DPP4PIM1FLT3CDK5ROCK1
SCHEMBL1579192 0.78 CLK4 (0.37) DPP4PIM1FLT3CDK5ROCK1
SCHEMBL25918346 0.77 GRM2 (0.32) GRM2
SCHEMBL21990516 0.77 KDR (0.33) DPP4PIM1FLT3ROCK1CLK4
SCHEMBL21990677 0.77 GRM2 (0.32) GRM2
SCHEMBL21990520 0.76 PIK3CD (0.34) DPP4PIK3CDPIK3CBPIK3CA
SCHEMBL29261238 0.76 CDK5 (0.35) DPP4PIM1FLT3CDK5ROCK1
SCHEMBL21990468 0.76 TAAR1 (0.34) DPP4KDRPIK3CDPIK3CBPIK3CA
SCHEMBL21990466 0.76 PARP1 (0.31) DPP4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3880676-B1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER (US) 2023-08-02 EP disclosed
EP-3880676-B1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER (US) 2023-08-02 EP disclosed
US-11142525-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2021-10-12 US disclosed
US-11142525-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2021-10-12 US disclosed
CN-113316576-A 2, 3-dihydro-1H-pyrrolo [3,4-c ] pyridin-1-one derivatives as HPK1 inhibitors for the treatment of cancer 辉瑞公司 2021-08-27 CN disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
WO-2020100027-A1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER INC. (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 DPP4 3549/4885PIM1 2262/4885FLT3 621/4885
US-11142525-B2 Azalactam compounds as HPK1 inhibitors CDKN1A, HIPK1, CMPK1 DPP4 3549/4885PIM1 2262/4885FLT3 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.